藥明康德(603259.SH)：擬斥800萬美元認購兩傢俬募基金份額
格隆匯 7 月 2日丨藥明康德(603259.SH)公佈，公司全資子企業WuXi PharmaTech Healthcare Fund I L.P.(“WuXi Fund I”)擬投資Nextech VI Oncology SCSp(“Nextech”)，投資金額為300萬美元，擬投資Biospring Partners Fund, L.P.(“Biospring”)，投資金額為500萬美元。
Nextech將主要投資腫瘤治療及與之相關領域的公司。公司認為其管理團隊在生命科學領域，尤其是腫瘤治療領域，有着廣泛的行業資源和豐富的投資經驗，這將有助於其發掘優秀的創新成果和投資標的，驗證相關投資機會背後的技術可行性。公司以較低比例投資Nextech作為其有限合夥人，有助於公司獲取風險投資收益的同時，增進公司對腫瘤相關領域發展動態的瞭解，進一步深耕併發掘腫瘤相關領域的合作機會，並支持公司的相關業務的拓展。
Biospring將主要投資面向製藥公司、生物技術公司和學術界的技術賦能型生命科學公司，該等公司側重開展服務、工具和企業軟件方面的業務。目前由於新技術(例如軟件和人工智能)已被運用於藥物發現和研發等過程，公司認為，面向製藥公司、生物技術公司和學術界的技術賦能型公司，通過提供相關服務、工具和企業軟件等方式，為各類製藥公司、生物技術公司賦能，可以令藥物發現和研發更為高效和安全。此外，此類技術賦能型公司不僅可以向大型製藥公司提供服務，還可以向小型生物技術公司提供服務，客户範圍廣泛而多樣；此類技術賦能型公司所專注的是研發所需的服務和工具，而非某款藥物的適應症和療效；因此，相較於投資專注於某款藥物療效的生物技術公司，投資此類技術賦能型公司的風險相對較低。除此之外，Biospring的管理團隊在生命科學和科技領域豐富的投資經驗、創業經驗有助於其發掘該領域優秀的創新成果。公司以較低比例投資Biospring作為其有限合夥人，一方面有望使公司獲得風險投資相關的財務收益；另一方面，Biospring的擬投資標的與公司存在潛在的業務協同效應。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
